Folate receptor-positive circulating tumor cell detected by lt-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 8, 2015, Pages 1163-1171

  Chen, Xiaoxia ^a   Zhou, Fei ^a   Li, Xuefei ^a   Yang, Guohua ^a   Zhang, Ling ^a   Ren, Shengxiang ^a   Zhao, Chao ^a   Deng, Qinfang ^b   Li, Wei ^b   Gao, Guanghui ^a   Li, Aiwu ^b   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Tongji University School of Medicine ^*  (China)

Author keywords

Circulating tumor cells; Folate receptor; Non small cell lung cancer; Polymerase chain.

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYFRA21 1 PROTEIN; FOLATE RECEPTOR; NEURON SPECIFIC ENOLASE; TUMOR MARKER; UNCLASSIFIED DRUG; ANTIGEN CYFRA21.1; CYTOKERATIN 19; ENOLASE; LIGAND; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIGAND TARGETED POLYMERASE CHAIN REACTION; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AREA UNDER THE CURVE; BLOOD; BRONCHIECTASIS; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; DOUBLE BLIND PROCEDURE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PNEUMONIA; PNEUMOTHORAX; PROCEDURES; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; TUBERCULOSIS, PULMONARY; TUMOR EMBOLISM; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOMARKERS, TUMOR; BRONCHIECTASIS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DOUBLE-BLIND METHOD; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; HUMANS; KERATIN-19; LIGANDS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PHOSPHOPYRUVATE HYDRATASE; PNEUMONIA; PNEUMOTHORAX; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; ROC CURVE; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84942915911     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000606     Document Type: Article

References (34)

1. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101
2. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010;20:96-99
3. Liberko M, Kolostova K, Bobek V. Essentials of circulating tumor cells for clinical research and practice. Crit Rev Oncol Hematol 2013;88:338-356
4. Riethdorf S, Fritsche H, Mller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-928
5. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791
6. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-3221
7. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309
8. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-1563
9. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-532
10. Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009;4:30-36
11. Mller V, Alix-Panabires C, Pantel K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 2010;46:1189-1197
12. Burgess DJ. Stem cells: competitive behaviour of cancer mutations. Nat Rev Cancer 2014;14:5
13. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 2011;105:1338-1341
14. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 2009;4:281-283
15. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010;107:18392-18397
16. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for nonsmall-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method. Int J Cancer 2011;129:1651-1660
17. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches. J Thorac Oncol 2012;7:306-315
18. OShannessy DJ, Yu G, Smale R, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 2012;3:414-425
19. Nunez MI, Behrens C, Woods DM, et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol 2012;7:833-840
20. Christoph DC, Asuncion BR, Hassan B, et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 2013;8:19-30
21. Lou J, Ben S, Yang G, et al. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One 2013;8:e80458
22. Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol 2013;6:697-702
23. OFlaherty JD, Gray S, Richard D, et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 2012;76:19-25
24. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007;253:180-204
25. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009;15:6980-6986
26. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-293
27. Rao CG, Chianese D, Doyle GV, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005;27:49-57
28. Ligthart ST, Bidard FC, Decraene C, et al. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol 2013;24:1231-1238
29. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377
30. Pailler E, Adam J, Barthlmy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-smallcell lung cancer. J Clin Oncol 2013;31:2273-2281
31. Christenson RH. Preamble: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for utilization of biomarkers in acute coronary syndromes and heart failure. Clin Biochem 2008;41:208-209
32. Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res 2007;27:1911-1915
33. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001;31:221-231
34. Molina R, Filella X, Aug JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24:209-218